Studies have found that YAP1 inhibitors reduce the expression of PD-L1 in tumor tissues, promote the infiltration of CD8 T cells and CD4 T cells into tumor tissue (108), which disrupt the immunosuppressive microenvironment of cancer and improve the efficacy of HCC treatment (109). The gene discussed is CD4; the disease is hepatocellular carcinoma.